{"organizations": [], "uuid": "a645800cf8f56bb4d395d1809548da59c0f7a79e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-avexis-q4-loss-per-share-255/brief-avexis-q4-loss-per-share-2-55-idUSASB0C7S7", "country": "US", "domain_rank": 408, "title": "BRIEF-Avexis Q4 Loss Per Share $2.55", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T23:03:00.000+02:00", "replies_count": 0, "uuid": "a645800cf8f56bb4d395d1809548da59c0f7a79e"}, "author": "", "url": "https://www.reuters.com/article/brief-avexis-q4-loss-per-share-255/brief-avexis-q4-loss-per-share-2-55-idUSASB0C7S7", "ord_in_thread": 0, "title": "BRIEF-Avexis Q4 Loss Per Share $2.55", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "reuters st", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "avexis inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 27, 2018 / 9:04 PM / Updated 11 minutes ago BRIEF-Avexis Q4 Loss Per Share $2.55 Reuters Staff Feb 27 (Reuters) - Avexis Inc: * AVEXIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS * Q4 LOSS PER SHARE $2.55 * ‍ON TRACK TO REQUEST PRE-BLA MEETING WITH FDA IN Q2 2018​ * ‍INTENDS TO INITIATE PIVOTAL TRIAL IN SMA TYPE 1 IN EUROPE AND MULTI-NATIONAL PRE-SYMPTOMATIC SMA STUDY IN FIRST HALF OF 2018​ * ‍ANTICIPATES IND SUBMISSIONS FOR RETT SYNDROME AND GENETIC ALS IN LATE 2018/EARLY 2019​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-27T23:03:00.000+02:00", "crawled": "2018-02-27T23:17:38.028+02:00", "highlightTitle": ""}